Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 1;56(suppl_5):v53-v66.
doi: 10.1093/rheumatology/kex202.

Assessment of skin involvement in systemic sclerosis

Gábor Kumánovics  1 , Márta Péntek  2 , Sangmee Bae  3 , Daniela Opris  4 , Dinesh Khanna  5 , Daniel E Furst  3 , László Czirják  1
Affiliations

Assessment of skin involvement in systemic sclerosis

Gábor Kumánovics et al. Rheumatology (Oxford). .

Abstract

Skin involvement in SSc is an important marker of disease activity, severity and prognosis, making the assessment of skin a key issue in SSc clinical research. We reviewed the published data assessing skin involvement in clinical trials and summarized the major conclusions important in SSc clinical research. A systematic literature review identified randomized controlled trials using skin outcomes in SSc. Analysis examined the validity of the different skin measures based on literature findings. Twenty-two randomized controlled trials were found. The average study duration was 10.2 (s.d. 4.5) months, mean (s.d.) sample size 32.4 (32.6) and 26.7 (27.8) in intervention and control arms, respectively. The 17-site modified Rodnan skin score is a fully validated primary outcome measure in diffuse cutaneous SSc. Skin histology seems to be an appropriate method for evaluation of skin thickness. These findings have important implications for clinical trial design targeting skin involvement in SSc.

Keywords: OMERACT filter; outcome measuring; randomized controlled trials; scleroderma; skin involvement; systemic sclerosis; validation.

PubMed Disclaimer

References

    1. Clements PJ, Medsger TA Jr, Feghali CA. Cutaneous involvement in systemic sclerosis. In: Systemic sclerosis (eds: Clements PJ, Furst DE), 2nd edition Lippincott Williams and Wilkins, 2004. pp. 129–50.
    1. Khanna D, Furst DE, Allanore Y. et al. Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. Rheumatology 2015;54:144–51. - PMC - PubMed
    1. Gniadecka M, Serup J, Søndergaard J.. Age-related diurnal changes of dermal oedema: evaluation by high-frequency ultrasound. Br J Dermatol 1994;131:849–55. - PubMed
    1. Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ.. Skin capillary changes in early systemic scleroderma. Electron microscopy and “in vitro” autoradiography with tritiated thymidine. Arch Dermatol 1976;112:1553–7. - PubMed
    1. Jadad AR, Moore RA, Carroll D. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12. - PubMed

Publication types